Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)

The summary for the Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44): The primary objective of this funding opportunity announcement is to support the development of improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner. The research supported will develop and enhance technologies that enable the production of functional stem cell-based therapies with potential commercial and clinical viability.
Federal Grant Title: Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-HL-15-030
Type of Funding: Grant
CFDA Numbers: 93.839
CFDA Descriptions: Blood Diseases and Resources Research
Current Application Deadline: Feb 20, 2017
Original Application Deadline: Feb 20, 2017
Posted Date: November 7th, 2014
Creation Date: Nov 7, 2014
Archive Date: Mar 23, 2017
Total Program Funding:
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following:
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:

1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;
2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;

3.
i. SBIR and STTR. Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR
ii. SBIR-only. Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; OR
iii. SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.
4. Has, including its affiliates, not more than 500 employees.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-030.html
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Sex Hormone Induced Thromboembolism in Pre-Menopausal Women (R61/R33)
Perinatal Stroke (R01)
Selected Topics in Transfusion Medicine (R01)
Selected Topics in Transfusion Medicine (R21)
Advancing Erythroid Cell Biology (R01)
Improved Therapy for Hemophilia and Hereditary Bleeding Disorders
Clinical Hematology Research Career Development Program (K12)
Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health
Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses f...
Environmental influences on Placental Origins of Development (ePOD) (R01)
Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existin...
Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existin...
Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2017 FederalGrants.com